Purple Biotech Ltd. (PPBT)
| Market Cap | 82.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 10.40M |
| Shares Out | 17.62M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 205,027 |
| Open | 4.63 |
| Previous Close | 4.67 |
| Day's Range | 4.56 - 4.75 |
| 52-Week Range | 3.60 - 7.25 |
| Beta | 1.92 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About PPBT
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and ...
Financial Performance
In 2020, Purple Biotech's revenue was $1,000,000, a change of 0.00% compared to the previous year's $1,000,000. Earnings were $28.00 million, an increase of 378.62%.
Financial StatementsNews
Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequen...
Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy
Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results
REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable...
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable ...
Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durabl...
Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients
Preliminary Data from First Part of Study Anticipated in Second Half of 2021
Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021...
TEL AVIV, Israel, April 13, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dur...
Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers
Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb
Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 20...
TEL AVIV, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” ”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and dur...
Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies by ov...
PPBT Stock: 9 Things for Investors to Know About Purple Biotech as Shares Surge
Purple Biotech (PPBT) stock is heading higher on Wednesday with heavy trading of the shares despite a lack of news about the company. The post PPBT Stock: 9 Things for Investors to Know About Purple Bio...
Purple Biotech to Present at the B. Riley Oncology Investor Conference
REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio...
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell
Virtual Bell-Ringing Ceremony in Celebration of Company's Recent Name Change to Purple Biotech
Kitov Announces Name Change to Purple Biotech Ltd.
New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies
Kitov Pharma to Participate in November Investor Conferences
TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug...
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24...
The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer The new cohort will explore the com...
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
Patent covers NT219's combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®)
New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference
Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
Top Line Results from First Part of the Study Expected in Second Half of 2021 Top Line Results from First Part of the Study Expected in Second Half of 2021
Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company’s Lead Oncology Assets, CM24...
Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries
Kitov Pharma Announces ADS Ratio Change
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...
Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results
TEL AVIV, Israel, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...
Is Kitov Pharmaceuticals Holdings (KTOV) Outperforming Other Medical Stocks This Year?
Is (KTOV) Outperforming Other Medical Stocks This Year?
Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody
Patent coverage for CM24 now extends to the U.S. and the EU